QUASR Diagnostics licensed QUASR technology developed at Sandia National Laboratories to fulfill the founder’s vision for disrupting the rapid diagnostics testing market. By amplifying the signals from an RT-LAMP (reverse-transcription loop mediated isothermal amplification) testing platform, QUASR makes the results brighter and easier to read.
“TRGR and our partner Sandia were instrumental in developing our technology for commercialization, saving us about a year in research and development time. This is permitting us to go to market much sooner than anticipated.”
Maulik Shah
CEO
QUASR Diagnostics Inc.
QUASR technology allows for rapid pathogen testing either at home or in the field with the accuracy of laboratory-based methods. Colorimetric QUASR assays can be read using a cellphone camera and a proprietary app, providing direct consumer access to high level diagnostic testing.
In the TRGR Project, Sandia Scientist Bryan Carson worked with QUASR on assay design and validation, developing assays for influenza A and B. Extensive bioinformatic sequence analysis was utilized to develop assays that would work against all clinically prevalent variants of influenza A after analyzing thousands of viral genomes during the Project.
So far, QUASR has developed and validated assays for West Nile Virus, chikungunya, monkeypox and COVID-19. These assays are ready for commercialization and use on existing third-party instruments. The company is also in the final stages of developing its colorimetric detection app, and has submitted SBIR (Small Business Innovation Research) grants for pathogens such as hantavirus and dengue virus.
QUASR technology is currently at TRL 5 for developed assays on existing instrumentation and TRL 4 for at-home and in-field use assays. QUASR was selected for the Startup Showcase at the BIO International Convention, and is seeking Series A investment for test portfolio expansion, platform development, and assay manufacturing.